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bstract
Autophagy is a physiological process in which cellular components are degraded by the lysosomal machinery. Thereby, organelles are
ecycled and monomers are produced in order to maintain energy production. Current studies indicate autophagy might suppress or augment
urvival of cancer cells. Therefore, by elucidating the role of autophagy in cancer pathogenesis, novel therapeutic intervention points may
e revealed. Leukemia therapy has advanced in recent years; but a definitive cure is still lacking. Since autophagy often is deregulated in
his particular type of cancer, it is clear that future findings will have clinical implications. This review will discuss the current knowledge of
utophagy in blood cancers.
2011 Elsevier Ireland Ltd. All rights reserved.
eywords: Autophagy; Leukemia; Cell death; Chemotherapeutic resistance
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l. Introduction
Autophagy is a signaling pathway which leads to degra-
ation of cellular components by lysosomal activity. Due
o an enhanced supply of monomers originating from the
ells own resources, this process is essential for survival
uring stress. In addition, autophagy has been shown to be
mportant in a variety of other cellular processes including
∗ Corresponding author. Tel.: +90 232 7507515; fax: +90 232 7507509.
E-mail addresses: yusufbaran@iyte.edu.tr, iytecancer@gmail.com
Y. Baran).
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oi:10.1016/j.critrevonc.2011.03.009he recycling of aged or damaged organelles, remodeling
f cellular structures during development, cell death, and
rotection against bacterial infection [1]. Since it is impor-
ant for homeostasis, defects in the autophagy pathway may
ead to diseases or malignancies [2]. The exact role of
utophagy in carcinogenesis, however, is still unclear but
ecent work in this field has helped substantially to improve
ur understanding. Leukemia is cancer of blood forming tis-
ues. According to their hematological origin, leukemia are
lassified as myeloid or lymphoid. The myeloid lineage is
esponsible for the production of blood cells other than lym-
hocytes. In correspondence with the hematopoietic lineage
2 Oncolo
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n which malignancy has occurred, leukemia are divided into
wo main groups: acute and chronic. Although there are novel
pproaches being developed for eradication of leukemic cells,
he route to a definitive cure is not easy and requires a better
nderstanding of intricate cellular mechanisms. Accumulat-
ng studies provided evidence of alterations in autophagy
athway upon malignant transformation and treatment with
hemotherapy [3]. These findings suggest the importance of
his process as a possible target for the development of novel
herapeutic approaches in malignancies.
This review will compile what is known about the
ntersection of autophagy and leukemia research in the fol-
owing sections. Various types and progression pathways
f leukemias will be described first, and the mechanisms
f autophagy will be briefly presented. Lastly, the involve-
ent of autophagy in hematological malignancies will be
iscussed.
. Types and progression pathways of leukemia
Leukemia is the general term for hematological cancers
ccurring in the tissues responsible for blood formation. Sim-
lar to other types of cancers, leukemia are characterized by
ncontrolled proliferation of cells, either in bone marrow or
he lymphatic system. There are two main classes of leukemia
iffering in their clinical and pathological properties. The
rst type, acute leukemia, is known to be more common
n children and characterized by the rapid proliferation of
mmature blood cells. The second type, chronic leukemia,
rogresses more slowly and involves leukemic cells which are
elatively differentiated. Further classification of leukemia is
one based on the tissue of origin as lymphoid or myeloid,
hich are explained in detail below.
Acute lymphocytic leukemia (ALL) occurs in cells called
ymphoblasts which normally differentiate into mature white
lood cells in healthy individuals. These undifferentiated
ells are found in excess numbers in the blood stream while
hey are confined to the bone marrow in healthy people.
he main causes of the majority of ALL cases are not pre-
isely known, but there are some genetic and chromosomal
berrations documented in immature blasts. Key transcrip-
ion factors or signaling pathways proximal to the membrane
re thought to be targets of such aberrations. Transloca-
ions observed in ALL lymphoblasts involve the genes TAL1,
ML1, MLL, and TEL each of which is important in different
tages of hematopoiesis [4]. The affected genes determine
he subtype of ALL as either B-lineage or T-lineage spe-
ific ALL. Burkitt’s lymphoma, one type of ALL, involves
translocation between the MYC gene and the genes encod-
ng light- or heavy chain immunoglobulin (Ig) proteins [5]. In
ddition to major chromosomal aberrations, single nucleotide
olymorphisms (SNP) were shown to be associated with
he development of ALL. For example, SNPs in the genes
RID5B and CEBPE were found to be significantly related
o ALL [6]. In addition to structural changes in the genome,
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pigenetic mechanisms are also important for ALL. In sev-
ral studies, unusual levels of DNA methylation in ALL cells
ere shown to result in the suppression of the WNT pathway,
15INK4B and P21CIP1 [7–9] and upregulation of miR-128
10].
Acute myeloid leukemia (AML) arises from the myeloid
ineage. Some myelodysplastic or myeloproliferative dis-
rders may turn into AML [11]. Chemotherapy may also
ause predisposition to AML. Especially chemotherapeu-
ic regimens involving topoisomerase II inhibitors [12] or
lkylating agents [13] were linked to such a predisposition.
xposure to ionizing radiation also increases the incidence
f AML as observed in the surviving population of Japan
fter atomic bombing [14]. There are also documented cases
n which AML was developed by multiple members of a
amily exceeding the predictions of random chance events
uggesting that there might also be a hereditary basis of the
isease [15,16]. In part because of these differences, this
alignancy is grouped under four categories according to
HO classification [17]: AML with recurrent genetic abnor-
alities, AML with multilineage dysplasia, therapy related
ML; and myelodysplastic syndrome (MDS), and lastly,
ML cases that are not suitable for classification in the previ-
usly groups. The most common genetic aberrations of AML
re t(8;21)(q22;q22) fusing the genes AML1 and ETO; inver-
ion of a portion of chromosome 16 causing the synthesis
f MYH11/CBFB fusion protein; t(15;17)(q22;q21) which
auses dominant expression of an abnormal retinoic acid
eceptor by fusing the genes PML and RARα; and translo-
ations involving the 11q23 locus containing the MLL gene.
hese chromosomal aberrations were observed in nearly 30
ercent of AML cases [18,19]. In addition to these major
tructural aberrations, numerous somatic mutations were
ound to be associated with AML including mutations in
he NPM1, KRAS2, CEBPA, ETV6, JAK2, and TET2 genes
20–26].
Besides the acute forms, leukemia can develop chroni-
ally in a less aggressive manner. The most frequent form of
eukemia is the chronic lymphocytic leukemia (CLL). Inci-
ence of CLL increases with age and is more common in men
han women. The disease is manifested by an increased num-
er of CD5-positive B-cells in the bone marrow and blood
tream. Uniquely, the accumulated cells are quiescent in the
0 phase unlike the aggressive nature of most cancerous cells
27]. Yet the presence of increased numbers of those cells in
he bloodstream suggests that these cells have a diminished
bility for self-destruction through apoptosis. Several studies
imed to shed light on the decreased ability of CLL cells to
ndergo apoptosis. Overexpression of antiapoptotic BCL-2 is
hought to be important in evading apoptosis [28] while cell-
o-cell contact [29], and exposure to certain cytokines [30]
re also linked to avoiding this type of cell death. Studies in
LL mouse models showed that the Tcl1-Akt, TNF-NF-B,
nd Bcl2-mediated antiapoptotic pathways are deregulated
31]. Besides these irregularities, genetic aberrations were
lso documented in the CLL cases including deletions in the
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ong arms of chromosomes 13, 11 and 7, and trisomy of
hromosome 12 [32]. CLL can be examined in two patho-
enetically different classes [33]. The slowly progressing
ubtype of CLL involves somatic mutations in immunoglob-
lin variable heavy chain genes. In contrast the subtype with
on-mutant immunoglobulin genes has poor prognosis and
equires earlier treatments.
Chronic myelogenous leukemia (CML) is the first type
f leukemia with pathogenesis resulting from a chromoso-
al translocation. The resultant translocation structure is
alled a Philadelphia chromosome (Ph) and occurs between
he long arms of chromosomes 9 and 22. This transloca-
ion drives the transformation to malignancy [34]. In Ph
+) CML, this translocation brings the BCR and ABL genes
ogether. This fusion gene encodes a constitutive tyrosine
inase that stimulates cell growth and division by phos-
horylating downstream targets [35]. Although the results
f the translocation are well known, the causative factors
ave not been yet enlightened. Increased incidence of CML
t atomic bombing sites suggests radiation exposure might
e partially responsible. The disease exhibits three phases:
hronic phase, accelerated phase, and blast crisis [36]. These
hases are distinguished from each other by their clinical
haracteristics and by the results of laboratory tests. The
hronic phase is the initial stage and the disease eventually
rogresses into the accelerated and blast crisis phases if left
ntreated. With disease progression, novel genetic aberra-
ions and mutations are acquired [37]. One speculation for the
echanism responsible for these changes is that the genomic
nstability of cancer cells causes new mutations and chromo-
omal rearrangements. According to another hypothesis, the
ame mechanisms which cause the translocation itself might
lso trigger new genetic aberrations. The latter hypothesis is
specially supported for cases in which the accelerated phase
uickly transforms into the blast crisis phase. The response of
ML therapy has improved in recent years with the availabil-
ty of targeted tyrosine kinase inhibitors (TKIs), including
matinib, nilotinib, and dasatinib. These chemotherapeutic
gents bind specifically to the ATP-binding domain of the
usion protein and prevent subsequent phosphorylation of the
ownstream players, thus directing leukemic cells to pro-
rammed cell death. By this mechanism, the numbers of
CR/ABL-positive cells are decreased to undetectable lev-
ls in most cases using imatinib treatment, which is the first
argeted drug developed. [38].
Leukemic cells may develop resistance to these
hemotherapeutic agents, an especially well-documented
henomenon for imatinib therapy. Resistance might be con-
erred by several mechanisms [39] including BCR/ABL
utations, overexpression of MDR (Multi Drug Resistance)
enes responsible for expelling the drug from the cytoplasm
nd deregulation of ceramide metabolism [40]. Moreover, a
ecent study has showed that the BCR/ABL oncoprotein is not
bsolutely required for the survival of CML stem cells. There-
ore, because of this insensitivity tyrosine kinase inhibitors
re unlikely to eliminate BCR/ABL(+) progenitors [41].
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hese findings indicate that there is a need for novel interven-
ion approaches for CML to obtain better leukemic clearance.
. Autophagy: types and mechanisms
Autophagy is the cellular process in which cellular com-
onents are degraded upon activation of the lysosomal
achinery. Targets of autophagy might be as small as pro-
eins or as large as organelles. Through this process, building
locks of degraded components are liberated which are then
e reutilized for the energy production. Therefore autophagy
as importance for survival under stress conditions such as
utrient deprivation [42]. The role of autophagy is not lim-
ted to supplying monomers for the production of energy.
utophagy was shown to be important in the recycling of
ged organelles, remodeling of cellular structures during
ifferentiation, defense against pathogens, and cell death
1,43,44]. Autophagic morphology was first observed in
he mammalian cells but elegant studies involving yeast
s a model system have primarily helped to delineate the
echanism [1,2,44]. Our current knowledge indicates that
utophagy has essential functions for maintaining homeo-
tasis, and deregulation of this pathway is implicated in the
rogression of diseases.
Autophagy can be classified into three groups: macroau-
ophagy, microautophagy, and chaperone-mediated
utophagy. In macroautophagy, a portion of cytoplasm
ncluding cytosolic proteins, protein aggregates and/or
rganelles is surrounded by a double-membraned structure
alled the autophagosome (see Fig. 1) [45]. Following
usion with the lysosomal membrane, the previously
equestered materials are enzymatically degraded. TOR
Target of Rapamycin-one type serine-threonine kinase) and
hosphatidylinositol 3-kinase (PI3K) proteins were found to
e important for signaling nutrient deprivation, and thus for
he induction of macroautophagy [46,47]. Induction of this
articular pathway is followed by nucleation, expansion and
ompletion of the autophagosome which is then fused with
he lysosome for degradation of autophagic bodies. In each of
hese stages, distinct sets of ATG proteins (the AuTophaGy-
elated protein family with at least 16 members in yeast) are
nvolved (see Fig. 1) [2]. Homologs of most of these genes
re also present in mammalian species and highly conserved
unctions. Macroautophagy is a major degradation pathway
ith a well-defined mechanism and the term “autophagy” is
ainly used to address this particular type. Microautophagy
efers to direct engulfment of the cytoplasmic portion by
he lysosome itself. Therefore the materials to be degraded
re not sequestered by the autophagosome; instead, they
re internalized to the lysosome by invaginations of the
ysosomal membrane. Because the internalized materials are
egraded along with portion of the lysosomal membrane,
his mechanism might be useful for resizing the lysosome
48]. The third type of autophagy, chaperone-mediated
utophagy, is useful for the targeted break-down of long-
278 H.A. Ekiz et al. / Critical Reviews in Oncology/Hematology 81 (2012) 275–285
Fig. 1. Signaling pathways regulating autophagy.
The process of autophagy is regulated by Autophagy-related genes (Atg) and their homologs in different eukaryotic cells. There are 35 different Atg family
genes discovered in Saccharomyces cerevisae and more than 15 in mamalian homologs.
Autophagosome formation
Autophagy begins with the generation of a phagophore assembly sites (PAS). Although the source of the first membrane structure is unclear, thereare strong
evidences that it comes from ER. Initiation of the phagophore structure depends on activity of Class-III phosphoinositide 3-kinase (PI3K) Vps34. Vps34 is
a protein complex that includes Atg6 (Beclin 1), Vps15 and Atg14 proteins. Besides PI3KII Vsp34, other Atg family proteins (Atg5, Atg12, Atg16) are also
involved in the formation of the phagophore structure.
Autophagosome elongation
There are two types of ubiquitylation-like reactions that control autophagy. Atg5 and Atg12 are involved in the first reaction and they are conjugated each other
in the presence of Atg7 and Atg10. The formation of this conjugation requires Vps34 activity
The second ubiquitylation-like reaction is the association of microtubule-associated protein 1 light chain 3 (MAP1-LC3; LC3) and phosphatidylethanolamine
(PE). The conjugation of Atg5-Atg12 may have roles in L3-I conjugation to PE. LC3-I is generated by Atg4 via cleavage of the C-terminus of LC3. Furthermore,
LC3-II is formed by covalent binding of LC3 to PE. Phagophores are extended with Atg5-Atg12-associated membranes which are targeted by LC3. LC3-II
is a unique protein that takes part in autophagosomes but not other vesicular structures Assesment of LC3-I to LC3-II conversion results in autophagosome
formation which gives an idea about autophagy level. As is mentioned above, there are two types of ubiquitylation that control autophagy and it is known that
these two systems are tightly related to each other. For example, Atg10 can ease association of LC3-I to PE.
Autophagosome maturation and fusion
Autophagosomes are transferred to the lysosomes from the cytoplasm via microtubules in a dynein-dependent manner and clumped near the nucleus, microtubule-
o lysosom
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4rganising centre. After this transfer, the autophagosome associates with a
he mechanism of autophagosome and lysosome fusion is still unknown.
ived proteins. Proteins to be degraded are translocated to
he lysosome through a protein complex called LAMP-2A
Lysososome-Associated Membrane Protein type 2A) which
s embedded in the lysosomal membrane [49]. Cytoplasmic
haperone Hsp70 and lysosomal chaperone Hsp73 are
esponsible for unfolding the target protein with a specific
otif and translocation into the lysosome [49,50]. This type
f autophagy provides another means of protein degradation
n addition to the ubiquitin-protease system (UPS) which
s a well-characterized mechanism of rapid degradation of
hort-lived proteins. However, these two mechanisms of
a
s
s
ae and components of the two different compartment are mixed. However,
rotein degradation are not mutually exclusive as shown by
indered UPS activity upon inhibition of autophagy [51,52].
. Autophagy and cancer
The relationship between autophagy and cancer has been
hot topic for years, and currently there are numerous
tudies shedding light onto different aspects of this relation-
hip. As controversial as it sounds, there is evidence that
utophagy might have roles in both tumor suppression and
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umor progression as extensively reviewed in other papers
3,53–55]. Some studies have shown that the activity of
he autophagic pathway decreases in most cancerous cells
56,57], suggesting that autophagy might be a suppressive
echanism for cancer progression. The tumor-suppressive
ffect of autophagy might be conferred by increased protein
egradation and/or by the clearance of damaged organelles
rom the cytosol. Increased protein degradation might be
seful for diminishing the amounts of proteins stimulating
ell growth which may lead to uncontrolled cell division.
utophagic disposal of organelles such as mitochondria and
eroxisomes that contain reactive oxygen species (ROS)
educes the risk of mutations and genomic instability; there-
ore it might be acting by preventing a tumor initiation.
romotion of tumorigenesis in several tissues of transgenic
ice with a disrupted Beclin-1 gene (ATG6), and a high
roportion of monoallelic Beclin-1 deletion in breast and
varian cancers agree with this hypothesis [58,59]. Beclin-
was also shown to interact with regulatory proteins of the
poptotic pathway [60,61], and this raises questions that the
umor suppressive function of Beclin-1 might not necessarily
esult from its involvement in autophagic activation. Instead
t might be regulating apoptosis to some extent. On the other
and, it is evident that other autophagy-specific genes exert
umor suppressive functions in the cell. One example is the
TG4C gene which encodes a protease required for the pro-
essing of LC3. Experiments with mice deficient in ATG4C
ave increased risk of developing fibrosarcomas along with
educed autophagic activity induced upon starvation [62].
In contrast to tumor suppressive effects, autophagy might
lso contribute to cancer cell survival. Especially for rapidly
rowing, solid tumors, autophagy might provide cells with
ecessary nutrients from their own resources in an environ-
ent where nutrients and oxygen are scarce due to poor
ascularization [63]. The same hypothesis is valid for metas-
asizing cells that experience nutritional deficiencies during
he process of migration. In support of this hypothesis, studies
howed that autophagic induction occurs upon detachment
rom the extracellular matrix [64], which is precisely what
appens for metastasizing cancer cells. Autophagy might
lso be useful for cancer cells by allowing disposal of dam-
ged mitochondria that would otherwise produce ROS and
arm the cell in such unfavorable conditions [65]. In addi-
ion, autophagy might also be involved in aggressiveness
nd chemotherapeutic resistance of malignancy [66]. Sug-
esting a possible role in the chemotherapeutic response,
utophagosomes were detected in cancer cells upon treatment
ith various chemotherapeutic agents including tamoxifen,
emozolomide and resveratrol [67–69].
Because autophagy may act for the benefit of cancer cells,
he possibility of targeting this pathway arises for a novel can-
er therapy. Some preliminary studies with cell lines have
hown that blockage of the autophagy pathway may sensi-
ize cancer cells of different origins to chemotherapy and
adiotherapy [70–73]. However, autophagy is a useful and
ecessary mechanism for the turnover of cellular compo-
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ents and clearance of protein aggregates that might cause
ell death in healthy cells. This latter case is especially impor-
ant in neurons. When the dual effects of autophagy in tumor
uppression and progression are taken into consideration; its
sage in cancer therapy remains to be elucidated. If autophagy
s to be employed as a common therapeutic approach, alter-
tion of autophagy should probably be targeted manner to
ancer cells to prevent undesired effects on healthy cells.
. Role of autophagy in leukemic cell death and
urvival
.1. Contribution of autophagy to cell death
In several studies, induction of autophagy was shown to
e important for the death of leukemic cells. In most of these
tudies, autophagy was manifested upon treatment with dif-
erent chemotherapeutic agents (Table 1). The widely used
yrosine kinase inhibitor imatinib was shown to induce cel-
ular autophagy in a dose-dependent manner in a variety
f cell lines [74]. This observation might be indicative of
novel mechanism of action for clearance of the malig-
ant cells by imatinib. However, the effect of autophagy in
matinib therapy must be further delineated further because
ncreased autophagy was not directly related to cytotoxicity
n the cell lines used for this study. However, the ability of
matinib to induce autophagy is exciting for providing novel
spects for research to reveal what is happening at the cellular
evel. The mTOR inhibitor everolimus (RAD001) is another
hemotherapeutic agent that was documented to kill child-
ood ALL cells through activation of autophagy and was
lso shown to provide a survival advantage to mice with ALL
y reducing the mass of leukemic cells [75,76]. A naturally
ccurring phytoalexin called eupalinin A inhibits growth of
cute promyelocytic leukemia (APL, a subtype of AML) cells
y initiating autophagy which is independent of Beclin-1 but
riggered by mitochondrial damage [77]. By a similar mech-
nism, an extract of the recreational herb khat (Catha edulis)
auses cell death via autophagy in AML cells by damag-
ng mitochondria [78]. Induction of autophagic cell death
ue to the loss of functional integrity of mitochondria was
lso documented by other groups. Some triterpenoid deriva-
ives, novel anticancer drug candidates, were shown to induce
utophagic death in CML cells by causing mitochondritoxic-
ty [79]. Brevinin-2R, one type of defensin isolated from the
kin of frog Rana ridibunda, kills T-cell leukemia and B-cell
ymphoma cells selectively through autophagy, again with
he involvement of mitochondria [80]. Some novel quinoline-
ike molecules with anti-cancer potential were also found to
e important for initiation of autophagy. This study, mito-
hondrial deformations were a concurrent with autophagic
nduction, possibly indicating that mitochondria are also
nvolved in this scenario [81]. Novel anti-cancer therapeutic
ompounds activating the autophagic pathway are not lim-
ted to the species previously stated. In addition to these,
280 H.A. Ekiz et al. / Critical Reviews in Oncology/Hematology 81 (2012) 275–285
Table 1
Effect of autophagy on cell death or survival/drug resistance with different chemotherapeutics and leukemia models.
Autophagic cytoprotection and drug resistance Autophagic cell death
Type of leukemia Drug treatment Type of leukemia Drug treatment
Childhood ALL Everolimus (RAD001) (75,76) CML INNO-406 (103)
APL (a subtype of AML) Eupalinin A (77) CML Imatinib (104)
AML Catha edulis extract (78) CML SAHA (HDAc inhibitor) (105)
CML Triterpenoids (79) APL Sodium selenite (106)
T-cell leukemia and B-cell Lymp. Brevinin-2R (80) T-cell ALL Triciribine (107)
Murine lymphoid leukemia Naphthalimides (82) B-cell CLL Dasatinib (112)
Human myeloid leukemia Vitamin D3 and K2 (83, 84)
Lymphoid leukemia Dexamethasone (85,86)
APL Platonin (87)
APL Arsenic tri-oxide (89,90)
Myeloid leukemia 2′-Deoxy-5-azacytidine (92)
B-cell CLL APO866 (93)
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cML GX15-070 (94)
KI resistant CML Resveratrol (96,97)
ome derivatives of naphthalimide were found to be potent
nhibitors of lymphoid leukemia in murine models [82] while
itamins D3 and K2 were shown to inhibit human myeloid
eukemias [83,84]. Glucocorticoids such as dexamethasone
lso contributed to autophagic death in leukemia of lymphoid
rigin [85,86]. In addition to these compounds, platonin, a
hotosensitizing compounds used in photodynamic therapy,
as also found to induce cell death in several leukemic cell
ines independent of the caspase pathway as is characteristic
f autophagy [87]. In another study, autophagy was shown
o be an important mechanism for cell death due to extensive
ecycling of cellular organelles damaged from photodynamic
herapy in mouse lymphocytic leukemia cells [88]. Arsenic
ri-oxide is another compound which was shown to induce
ell death in APL cells via autophagy [89,90]. However
ome other arsenicals did not show tumor suppressive effects
y activation of the autophagic pathway in a promyelocytic
eukemia cell line [91].
Epigenetic alterations were also found to be important
or inducing cell death through autophagy. In a recent study,
rolonged exposure of myeloid leukemia cells to the DNA
emethylating agent 2′-deoxy-5-azacytidine (DAC) resulted
n increased erythroid and megakaryocytic differentiation
s well as increased leukemic cell death by promoting the
utophagic pathway [92]. APO866, an inhibitor of nicoti-
amide phosphoribosyl transferase, was shown to contribute
o autophagic cell death synergistically with apoptotic activa-
or TRAIL in B-cell CLL [93]. In this recent report, APO866
esulted in the depletion of NAD and cellular ATP levels
eading to induction of autophagy. This process did not take
lace in healthy leukocytes suggesting that such a com-
ination therapy might be a selective approach for CLL
reatment. The Bcl-2 homology domain 3 (BH3) mimetic,
X15-070, was shown to induce autophagic cell death along
ith increased apoptosis in AML cells [94]. However in
reast and cervical cancer cell lines, another BH3 mimetic,
ossypol, was shown to induce autophagy, leading to cyto-
rotection, suggesting that targeting similar mechanisms may
t
w
k
cave opposite outcomes in different cell types [95]. Tyrosine
inase inhibitor sensitive and resistant CML cells were shown
o undergo autophagic cell death after treatment with resver-
trol, a naturally occurring plant phytoalexin. This cell death
ccurred JNK-mediated overexpression of p62 and activa-
ion of AMPK [96,97]. This suggests that autophagy might
e an important pathway for cell death in different chemother-
peutic modalities. Indeed, in a recent study, genome-wide
nalysis of DNA methylation patterns revealed that hyper-
ethylation of autophagy-related genes correlated with poor
rognosis in CML cells indicating that blocking autophagy
educes the leukemic cell clearance [98]. Refractory ALL
as sensitized to glucocorticoids and other cytotoxic drugs
y Bcl-2 antagonists in a process involving rapid activa-
ion of autophagy-dependent necroptosis which overcame
he block in mitochondria-dependent apoptosis. These results
uggested that manipulation of autophagy could have a trans-
ational aspect for multi-drug resistant leukemias [99].
.2. Importance of autophagy in leukemic cell survival
nd drug resistance
Because autophagy acts to the benefit of cells under nor-
al physiological conditions, it may also provide advantages
o cancerous cells. There are reports indicating that autophagy
cts as a pro-survival mechanism and may contribute to
hemotherapeutic resistance in various leukemias. In some
tudies, it was shown that inhibition of autophagy enhanced
he therapeutic potential of tyrosine kinase inhibitors in Ph
+) malignancies [100–102]. In another study, the autophagic
esponse upon application of the second-generation tyrosine
inase inhibitor INNO-406 was protective for BCR/ABL
ositive cells [103]. Experiments done in various leukemia
ell lines and mouse fibroblasts have revealed that ima-
inib treatment increases the amount of autophagosomes
hich provide a cytoprotective effect [104]. In this study,
nockdown of autophagy-specific genes did not result in
omplete loss of the protection, suggesting that autophagy
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as partially responsible for this observation. Targeting
utophagy in experimental settings involving chemothera-
eutics other than tyrosine kinase inhibitors was also shown
o have potential to enhance the chemotherapeutic outcome.
he tumor-suppressive efficacy of the histone deacetylase
nhibitor, SAHA was augmented when applied in combina-
ion with autophagy inhibitors in CML cells [105]. Selenium
s another chemotherapeutic agent for which the exact mech-
nism of action is currently the focus of active research.
hile application of sodium selenite resulted in downregula-
ion of autophagy in APL cells, selenium-induced apoptosis
as shown to be enhanced upon suppression of autophagy
106]. In this study, PI3K/Akt was found to be upregu-
ated in autophagy and downregulated in apoptosis in the
PL cell line NB4. Moreover, autophagy was linked to
he survival of NB4 cells. A recent report indicated that
he Akt inhibitor triciribine increased apoptosis in T-cell
LL by a process in which autophagy played a defen-
ive role as shown by increased apoptosis when autophagy
as inhibited [107]. Similarly, suppression of autophagy
ith shRNAs and specific inhibitors resulted in blocking
f PML-RAR oncoprotein degradation and granulocytic
ifferentiation in myeloid leukemia cells [108]. CML cells
xpressing BCR/ABL oncoprotein at high levels were shown
o induce autophagy in order to recover from targeted and
ontargeted treatment options, indicating the protective effect
f autophagy in CML [109]. These findings are supported by
nother recent report that indicated that the release of specific
amage-associated molecular pattern molecules (DAMPs)
fter chemotherapy conferred drug resistance to leukemic
ells by activating the autophagic pathway [110,111]. In addi-
ion to these findings, B-cell CLL was also shown to develop
esistance to the tyrosine kinase inhibitor dasatinib by acti-
ating autophagy [112] In another report, overexpression of
he melanoma differentiation-associated gene-7/interleukin-
4 (mda-7/IL-24) was shown to induce autophagy and confer
urvival advantage to leukemic cells [113]. Mda-7/IL-24 and
uppression of autophagy may have potential for leukemia
herapy since it selectively induces apoptosis in a variety of
ancer cells. In addition, autophagy was shown to exert pro-
ective functions on cellular physiology upon photodynamic
herapy (PDT). However, it was also shown that extensive
ecycling of cellular components might cause cell death if
he PDT dosage is increased [114]. In the light of the cur-
ent literature, the cytoprotective effect of autophagy might
lso be important for conferring chemotherapeutic resistance.
hus targeting autophagy might provide novel approaches to
vercome the resistance frequently observed in the clinic.
his phenomenon is addressed by various other studies and
eview papers [100,101,115–118].. Conclusion and future directions
Autophagy is currently one of the hottest topics in the
cientific arena, and more specifically, in cancer research.
t
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ccumulating evidence indicates that this process is involved
n numerous physiological and pathophysiological condi-
ions. Increasing numbers of studies in this area are currently
nable to solve the controversial nature of autophagy from
he perspective of development of novel cancer therapeutics.
ur current knowledge leaves no doubt that autophagy has
reat potential for the development of novel therapeutics.
owever, further research should be done to delineate the
ole of autophagy in cancer cell death and cell survival. One
mportant point to be elucidated is the determination whether
utophagy is directly responsible for the reported observa-
ions, or if it is a secondary response of cells to the specified
onditions. In addition, we need to gain a deeper under-
tanding of autophagy in the discrimination of cell death and
ell survival. By achieving this, manipulation of autophagy
ight emerge as a future cancer therapeutic. Indeed, there
re three phase II clinical trials that are currently recruiting
atients and which investigate the efficacy of hydroxychloro-
uine, an inhibitor of autophagy [119], in CML (clinical
rial identifier NCT01227135); in relapsed refractory mul-
iple myeloma (NCT00568880); and in untreated B-CLL
NCT00771056). The latter trial will indicate the poten-
ial of autophagy inhibition itself as an anticancer approach
ecause B-CLL patients who have not previously received
ny chemotherapy or immunotherapy are being included in
he trial. The other two trials aim to inhibit autophagy along
ith the application of previously known chemotherapeu-
ic drugs to determine whether the refractory phenotype of
eukemia can be reversed by altering the autophagy pathway.
n addition to trials, there are numerous others that test the
ffects of inhibition of autophagy in various cancer models
ther than leukemias (reviewed in [120]).
For more than a decade, autophagy has been thought to
e an important process in cancer biology. Numerous studies
ave shown that autophagy contributes to both cancer cell sur-
ival and cell death. This multifaceted feature of autophagy
s contributed by two factors: the complexity of the sys-
em which has numerous critical regulators and cross-talk
ith other cellular processes which determine cell survival.
he functions of autophagy seem to differ among cell types
f different origin as similar experimental designs yielded
ompletely different observations when cellular origin was
ltered. This suggests that different cellular pathways might
e modulating autophagy to some extent rendering it either as
pro-survival or toxicity mechanism. More research should
e done to dissect such mechanistic differences between
arious forms of cancer cells and non-malignant cells in
he body. As appealing as it sounds for cancer therapy,
ltering autophagy could possibly have undesired outcomes
or healthy cells if it is nor regulated in a specific man-
er. The search for autophagy-activating pathways that are
electively activated in cancer cells would provide potential
argets for the development of selective therapeutics. One
ood example for this approach is the search for hypoxia-
nducible pathways that activate autophagy [121,122]. Such
esearch might provide a selective means for eradication
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f solid tumors since such tumors experience hypoxia and
utrient deprivation in poorly vascularized tumor tissue and
uring metastasis. Similarly, understanding the distinct path-
ays activating autophagy in different forms of leukemia is
ikely to produce novel targets for leukemia therapies, and
here is a need for more detailed studies that shed light on
ross-talk in malignancy. Another important future perspec-
ive for this area would be discriminating the involvement
f autophagy in different stages of leukomogenesis. Before
nhibiting the pathway, one would want to know which stage
f malignancy requires autophagy for cytoprotective effects.
oreover, there might be a need for novel powerful tools
o assess whether autophagy is the causative factor for the
bserved effects or if it is a secondary response of cells
nd not particularly important for the decision of cellular
ate. In the latter case, drug resistance may appear simul-
aneously with autophagic induction; but inhibition of this
athway might not be an efficient intervention since the main
athways driving the process are not blocked. This suggests
hat we need to know more about other cellular processes
hat interact with autophagy and to decipher the cross-talk
mong different mechanisms in order to develop an effi-
ient approach to increase leukemic cell death and reversal
f drug resistance. With this knowledge and understanding
f the molecular genetics underlying this complex process,
linicians could identify patients who might benefit from an
pproach involving alteration of the autophagy pathway with
nhibitors.
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